Liquidia Technologies is developing engineered particle-based vaccines and therapeutics that have the potential to dramatically improve the quality of human life. Utilizing a novel technology known as the PRINT® platform, Liquidia is creating rationally-design carriers for improved delivery of small molecule and biological cargos.

By designing highly specific particles that deliver therapies to an intended target, Liquidia is uncovering ways to optimize the safety and efficacy of vaccines and therapeutics. Liquidia's PRINT platform makes it possible for the first time to design particles with independent and precise control of particle size, shape, chemistry, surface functionality, and flexibility. The ability to modify these key particle attributes is allowing Liquidia and its partners to develop more optimized, safe, and effective vaccines and therapies for a wide variety of diseases.
Learn more about Life Science programs >

Liquidia is also exploring novel applications in the Materials Science sector, including alternative energy technologies and solutions.
Learn more about Materials Science programs >

Liquidia was founded in 2004 on the discoveries of Professor Joseph DeSimone and colleagues at the University of North Carolina, Chapel Hill. The company is located in Research Triangle Park, North Carolina.